Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
Assessing the role of macular pigment optical volume in non-neovascular age-related macular degeneration: associations with rod-mediated dark adaptation and disease progression.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stettler Isabella, Romano Francesco, Nigalye Archana, Lains Ines, Choi Hanna, Ding Xinyi, Bennett Cade F, Overbey Katherine M, Ploumi Ioanna, Garg Itika, Katz Raviv, Kasetty Megan, Vingopoulos Filippos, Vavvas Demetrios G, Miller Joan W, Husain Deeba, Miller John B
Аннотация
PURPOSE: To characterize macular pigment optical volume (MPOV) across non-neovascular age-related macular degeneration (AMD) stages and in healthy controls, and to explore its associations with dark adaptation (DA) time and long-term AMD progression.
DESIGN: Cross-sectional and longitudinal observation study including patients with non-neovascular AMD (early, intermediate, advanced) per Beckman classification and age-similar controls with no retinal disease. All eyes had good-quality dual-wavelength autofluorescence imaging (Spectralis Investigational MPOD Module).
METHODS: DA was assessed using the AdaptDx® extended protocol (LumiThera, Poulsbo, WA). MPOV was calculated for three concentric circles centered on the fovea at radii of 1°, 2°, and 6°. AMD progression was determined through consultation of follow-up clinical and imaging data. Mixed-effects linear regression models evaluated baseline differences between AMD and control eyes, and across non-neovascular AMD stages. Progression risk was assessed using mixed-effectsCox proportional hazards models adjusted for age, AREDS2 use, lens opacities, and fellow eye status.
RESULTS: Our analysis included 110 AMD eyes (58 patients; median age 72, 56.9% female) and 51 control eyes (26 patients; median age 64, 53.9% female). AMD eyes had significantly higher MPOV than controls when calculated at all eccentricities (1, 2, and 6°, all p<0.01). In controls, higher MPOV at all eccentricities was associated with shorter DA time (p<0.05) - a relationship not observed in AMD eyes. Of 108 AMD eyes with follow-up (median, 53.1 months), 24 eyes (22.9%) progressed to a more advanced stage. Higher MPOV values at all eccentricities were independently associated with increased progression risk (all p<0.05) CONCLUSIONS: AMD eyes show greater MPOV values than controls, especially in intermediate stages. While MPOV correlated with better DA performance in healthy eyes, this relationship was absent in AMD, suggesting a more complex interaction in diseased retina.
DESIGN: Cross-sectional and longitudinal observation study including patients with non-neovascular AMD (early, intermediate, advanced) per Beckman classification and age-similar controls with no retinal disease. All eyes had good-quality dual-wavelength autofluorescence imaging (Spectralis Investigational MPOD Module).
METHODS: DA was assessed using the AdaptDx® extended protocol (LumiThera, Poulsbo, WA). MPOV was calculated for three concentric circles centered on the fovea at radii of 1°, 2°, and 6°. AMD progression was determined through consultation of follow-up clinical and imaging data. Mixed-effects linear regression models evaluated baseline differences between AMD and control eyes, and across non-neovascular AMD stages. Progression risk was assessed using mixed-effectsCox proportional hazards models adjusted for age, AREDS2 use, lens opacities, and fellow eye status.
RESULTS: Our analysis included 110 AMD eyes (58 patients; median age 72, 56.9% female) and 51 control eyes (26 patients; median age 64, 53.9% female). AMD eyes had significantly higher MPOV than controls when calculated at all eccentricities (1, 2, and 6°, all p<0.01). In controls, higher MPOV at all eccentricities was associated with shorter DA time (p<0.05) - a relationship not observed in AMD eyes. Of 108 AMD eyes with follow-up (median, 53.1 months), 24 eyes (22.9%) progressed to a more advanced stage. Higher MPOV values at all eccentricities were independently associated with increased progression risk (all p<0.05) CONCLUSIONS: AMD eyes show greater MPOV values than controls, especially in intermediate stages. While MPOV correlated with better DA performance in healthy eyes, this relationship was absent in AMD, suggesting a more complex interaction in diseased retina.